Get the Stockscreener App
1.685
0.30%
0.005
Pliant Therapeutics Inc stock is traded at $1.685, with a volume of 242.52K.
It is up +0.30% in the last 24 hours and up +10.86% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.68
Open:
$1.675
24h Volume:
242.52K
Relative Volume:
0.29
Market Cap:
$103.13M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5453
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
-6.39%
1M Performance:
+10.86%
6M Performance:
-0.30%
1Y Performance:
-88.40%
1-Day Range:
$1.64
$1.73
1-Week Range:
$1.61
$1.83
52-Week Range:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.68 | 103.13M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Why Pliant Therapeutics Inc. (9PT) stock could be top winner2025 Technical Patterns & Low Drawdown Investment Ideas - newser.com
Why Pliant Therapeutics Inc. stock is in analyst buy zoneMarket Volume Summary & Safe Swing Trade Setup Alerts - newser.com
How rising interest rates impact Pliant Therapeutics Inc. stock2025 Biggest Moves & AI Powered Market Entry Strategies - newser.com
Pliant Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Is Pliant Therapeutics Inc. stock near bottom after declineJuly 2025 Outlook & Daily Momentum Trading Reports - newser.com
Why Pliant Therapeutics Inc. stock is favored by top institutions2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
What indicators show strength in Pliant Therapeutics Inc.July 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Does Pliant Therapeutics Inc. show high probability of reboundJuly 2025 Macro Moves & Accurate Intraday Trade Tips - newser.com
Will Pliant Therapeutics Inc. (9PT) stock outperform global peersJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - newser.com
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Heatmap analysis for Pliant Therapeutics Inc. and competitorsMarket Movement Recap & Daily Chart Pattern Signal Reports - newser.com
Chart overlay techniques for tracking Pliant Therapeutics Inc.July 2025 Update & Fast Entry High Yield Tips - newser.com
Is Pliant Therapeutics Inc. stock cheap at current valuationShare Buyback & Precise Trade Entry Recommendations - newser.com
Analyzing recovery setups for Pliant Therapeutics Inc. investorsOptions Play & Weekly Chart Analysis and Guides - newser.com
Will Pliant Therapeutics Inc. stock deliver shareholder valueTrade Signal Summary & Real-Time Stock Price Movement Reports - newser.com
Technical signs of recovery in Pliant Therapeutics Inc.Jobs Report & Weekly Breakout Opportunity Watchlist - newser.com
Price momentum metrics for Pliant Therapeutics Inc. explained2025 Institutional Moves & Accurate Entry/Exit Alerts - newser.com
Pliant Therapeutics (PLRX) Expected to Announce Earnings on Thursday - MarketBeat
Can Pliant Therapeutics Inc. stock maintain operating marginsJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - newser.com
Is Pliant Therapeutics Inc. (9PT) stock worth buying before Fed actionWeekly Loss Report & Fast Momentum Stock Entry Tips - fcp.pa.gov.br
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):